The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of autologous CD8+ and CD4+ transgenic T cells expressing high-affinity KRAS G12V mutation-specific T cell receptors (FH-A11KRASG12V-TCR) in patients with metastatic pancreatic, colorectal, and non-small cell lung cancers with KRAS G12V mutations.
 
Rachael Safyan
Honoraria - Curio Science
Consulting or Advisory Role - Agenus; Guardant Health; Ipsen; Mirati Therapeutics
Research Funding - Exelixis (Inst); Replimune (Inst); Verastem (Inst)
 
Mary Redman
No Relationships to Disclose
 
Andrew Coveler
Consulting or Advisory Role - Abbvie; Halozyme; Merrimack; Seagen
Research Funding - AbGenomics International (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); Newlink Genetics (Inst); Nextrast (Inst); Novocure (Inst); Nucana (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Abbvie; Halozyme; Nucana
 
Stacey Cohen
Consulting or Advisory Role - Abbvie; Agenus; Exact Sciences; Guardant Health; Incyte; Merck; Pfizer; Regeneron; Taiho Oncology
Research Funding - Biomea (Inst); BioNTech SE (Inst); Natera (Inst); Pfizer (Inst); Tempus (Inst)
Expert Testimony - The Cline Law Firm
Travel, Accommodations, Expenses - Biomea Fusion; Natera
 
Sylvia Lee
Research Funding - Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst); Kite, a Gilead Company (Inst); PACT Pharma (Inst); Seagen (Inst); Tmunity Therapeutics, Inc. (Inst)
 
Cecilia Yeung
Stock and Other Ownership Interests - TwinStrand Biosciences
Honoraria - Abbvie; Bristol-Myers Squibb; Merck
Consulting or Advisory Role - TwinStrand Biosciences
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Kineta (Inst); OBI Pharma (Inst); Pfizer (Inst); Sensei Biotherapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Fred Hutchinson Cancer Center
 
Thomas Schmitt
Consulting or Advisory Role - Affini-T Therapeutics; SignalOne Bio
Research Funding - Affini-T Therapeutics; Cullinan Oncology; Lonza; SignalOne Bio
Patents, Royalties, Other Intellectual Property - Affini-T Therapeutics; Cullinan Oncology; Lonza
 
Aude Chapuis
No Relationships to Disclose
 
Philip Greenberg
Stock and Other Ownership Interests - Affini-T Therapeutics; Catalio; Earli; Elpiscience; Fibrogen; ImmunoSCAPE; Metagenomi; Nextech Invest; RAPT Therapeutics
Honoraria - Genentech
Consulting or Advisory Role - Affini-T Therapeutics; Catalio; Earli; Elpiscience; FibroGen; FLX Bio; ImmunoSCAPE; Metagenomi; Nextech Invest; RAPT Therapeutics
Research Funding - Affini-T Therapeutics; Lonza
Patents, Royalties, Other Intellectual Property - Adaptive Biotechnologies; Affini-T Therapeutics; Juno Therapeutics has licensed technology on T cell therapy originating from my laboratory; Lonza
Travel, Accommodations, Expenses - Elpiscience; FLX Bio; Genentech; Nextech Invest; RAPT Therapeutics
 
E. Gabriela Chiorean
Consulting or Advisory Role - AADi; Astellas Pharma; BPGbio; Bristol-Myers Squibb/Celgene; IgM Biosciences; Ipsen; Merus; Pfizer; Purple Biotech; Regeneron; Takeda
Research Funding - Affini-T Therapeutics (Inst); BioAtla; Boehringer Ingelheim (Inst); Erasca, Inc (Inst); FibroGen (Inst); Genentech (Inst); Gilead/Forty Seven (Inst); Lonza (Inst); Merck (Inst); Mirati Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Merus